Argus Research Maintains Buy on Amgen, Raises Price Target to $340
Portfolio Pulse from Benzinga Newsdesk
Argus Research has maintained its Buy rating on Amgen (NASDAQ:AMGN) and raised the price target from $300 to $340, indicating a positive outlook for the stock.
June 27, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Argus Research has maintained its Buy rating on Amgen and raised the price target from $300 to $340, suggesting a positive outlook for the stock.
The raised price target from $300 to $340 by Argus Research indicates increased confidence in Amgen's future performance. This is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100